Charles Schwab’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-178,952
| Closed | -$4.31M | – | 3747 |
|
|
2023
Q1 | $4.31M | Buy |
178,952
+2,488
| +1% | +$31.2K | ﹤0.01% | 2276 |
|
|
2022
Q4 | $1.87M | Buy |
176,464
+11,358
| +7% | +$91.7K | ﹤0.01% | 2592 |
|
|
2022
Q3 | $743K | Buy |
165,106
+21,098
| +15% | +$96.1K | ﹤0.01% | 2889 |
|
|
2022
Q2 | $577K | Sell |
144,008
-2,055
| -1% | -$9.74K | ﹤0.01% | 3020 |
|
|
2022
Q1 | $1.07M | Buy |
146,063
+2,537
| +2% | +$15.2K | ﹤0.01% | 2824 |
|
|
2021
Q4 | $807K | Buy |
143,526
+5,168
| +4% | +$32.8K | ﹤0.01% | 2989 |
|
|
2021
Q3 | $886K | Sell |
138,358
-236,596
| -63% | -$1.52M | ﹤0.01% | 2918 |
|
|
2021
Q2 | $3.16M | Buy |
374,954
+10,925
| +3% | +$88.1K | ﹤0.01% | 2569 |
|
|
2021
Q1 | $3.82M | Buy |
364,029
+47,233
| +15% | +$665K | ﹤0.01% | 2425 |
|
|
2020
Q4 | $5.37M | Buy |
316,796
+2,256
| +0.7% | +$33.8K | ﹤0.01% | 2183 |
|
|
2020
Q3 | $4.04M | Buy |
314,540
+212,320
| +208% | +$2.68M | ﹤0.01% | 2178 |
|
|
2020
Q2 | $1.44M | Buy |
102,220
+87,667
| +602% | +$1.11M | ﹤0.01% | 2529 |
|
|
2020
Q1 | $134K | Hold |
14,553
| – | – | ﹤0.01% | 3078 |
|
|
2019
Q4 | $217K | Buy |
+14,553
| New | +$130K | ﹤0.01% | 3028 |
|
Other funds holding PRVB
Charles Schwab's PRVB Position: Q2 2023 in Review
Charles Schwab sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 178,952 shares — an estimated $4.31M sold.
Charles Schwab first reported a position in PRVB in Q4 2019 and held it in 14 quarters. The position peaked at $5.37M in Q4 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Charles Schwab reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Charles Schwab sold 178,952 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $4.31M.
- Charles Schwab first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
- Charles Schwab's Provention Bio, Inc. Common Stock position peaked at $5.37M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.